Bibliographic Details
| Title: |
Aprea Therapeutics announces clinical hold on lymphoid malignancy programme. |
| Source: |
Chemical Business NewsBase (UK), August 12, 2021, 2pp |
| Abstract: |
Aprea Therapeutics Inc, a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumour suppressor protein, p53, announced on 12 Aug 2021 that the US Food and Drug Administration (FDA) has placed a clinical hold on its clinical trial evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies... |
| Database: |
NewsBank |
